Search

Displaying results 1621 - 1630 of 7687 in total
  1. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … [A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A.

  2. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [A199002] Daratumumab was granted FDA approval on 16 November 2015. … Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.

  3. Drug

    Andrographolide

    go.drugbank.com/drugs/DB05767
    Investigational

    The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.

  4. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    FDA approved on February 1, 2013.

  5. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.

  6. Drug

    Cisatracurium

    go.drugbank.com/drugs/DB00565
    ApprovedInvestigational

    [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times its neuromuscular blocking potency. … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597].

  7. Drug

    Iodine povacrylex

    go.drugbank.com/drugs/DB09537
    Approved

    It is a broad spectrum antiseptic and can provide almost 99.9% antiseptic conditions. It is intended for local use only. … DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection

  8. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986] … However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent

  9. Target

    NADPH-flavin oxidoreductase

    go.drugbank.com/bio_entities/BE0002629
    TargetVibrio harveyi

    Catalyzes the NADPH-dependent reduction of FMN to FMNH(2). Involved in bioluminescence by providing FMNH(2) to luciferase.

    Synonyms: FRP
  10. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.